Comparison of lipid profile in two treatment groups
Compared to statins group, lipid profile improved significantly in the patients imitated with PCSK-9 inhibitor therapy (Figure 1). The LDL level was reduced by 42.57% in PCSK-9 inhibitor group and 30.81% (P <0.001) in statins group after 6 month follow-up. The HDL level increased by 10.00% and 9.01% , and TC level decreased by 25.15% and 21.02% (P <0.001) in PCSK-9 inhibitor group and statins group.
More patients initiated with PCSK-9 inhibitor achieved the targeted LDL-C ≤1.0mmol/L and 1.4 mmol/L. The proportion of LDL≤1.0mmol/L increased from 5.29% to 29.26% in the PCSK-9 inhibitor group and 0.23% to 6.11% in statins group over 6 months follow-up (P <0.001, efigure 1C), and the proportion of LDL≤1.4mmol/L increased from 10.36% to 47.69% and 2.99% to 18.43% (P <0.001).